Bristol Myers Squibb reports data from Phase III multiple sclerosis trial

Bristol Myers Squibb, which has facilities in Seattle, recently announced new data from its Phase III DAYBREAK clinical trial for multiple sclerosis treatment (MS). According to the company’s press release, the clinical trial data showed treatment with Zeposia (ozanimod) demonstrated a low annualized relapse rate.


“These DAYBREAK efficacy, safety and rebound data underscore a consistent and sustained safety and efficacy profile and add to the body of evidence supporting Zeposia’s role in the treatment armamentarium. We remain focused on advancing care and delivering meaningful innovations in neuroscience, including for the millions of people impacted by relapsing forms of multiple sclerosis,” said Jonathan Sadeh, MD, MSc, senior vice president and head of global program leaders, Immunology, Cardiovascular and Neuroscience development at Bristol Myers Squibb in a press release.

READ THE STORY at Clinical Trials Arena »